Mentore Ribolsi

Dr. Mentore Ribolsi

Department of Digestive Diseases, Campus Bio Medico University of Rome, 00128 Roma, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2022 in Digestive and Liver Disease
Verified
Journal Article
Closed access
Mentore RibolsiMentore Ribolsi
Mentore Ribolsi
ESEdoardo Savarino
Edoardo Savarino
MFMarzio Frazzoni
Marzio Frazzoni
MCMichele Cicala
Michele Cicala

1 September 2023 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
Mentore RibolsiMentore Ribolsi
Mentore Ribolsi
LMLorenzo Marchetti
Lorenzo Marchetti
ESEdoardo Vincenzo Savarino
Edoardo Vincenzo Savarino
CGC. Prakash Gyawali
C. Prakash Gyawali
MCMichele Cicala
Michele Cicala
INTRODUCTION: Gastroesophageal reflux disease (GERD) severity increases with esophageal body hypomotility, but the impact of Chicago Classification (CC) v4.0 criteria on GERD diagnosis is incompletely understood. METHODS: In patients with GERD evaluated with high-resolution manometry and pH-impedance monitoring, CCv3.0 and CCv4.0 diagnoses were compared. RESULTS: In 247 patients, hypomotility diagnosis decreased from 45.3% (CCv3.0) to 30.0% (CCv4.0, P < 0.001). In contrast, within patients with ineffective esophageal motility, proportions with pathological acid exposure increased from 38% (CCv3.0) to 88% (CCv4.0); baseline impedance and esophageal clearance demonstrated similar findings (P < 0.05 for each comparison). DISCUSSION: CCv4.0 hypomotility criteria are more specific in supporting GERD evidence compared with CCv3.0.

Verified
Journal Article
Open access
PDF file
Michele CicalaMichele Cicala
Michele Cicala
MGManuele Gori
Manuele Gori
PBPaola Balestrieri
Paola Balestrieri
AAAnnamaria M Altomare
Annamaria M Altomare
ATAlessandro Tullio
Alessandro Tullio
RFRicard Farre
Ricard Farre
Vedolizumab (VDZ) is used for treating inflammatory bowel disease (IBD) patients. A study investigating colonic epithelial barrier function ex vivo following VDZ is lacking. This work aims to evaluate ex vivo the colonic epithelial barrier function in IBD patients at baseline and during VDZ treatment, and to investigate the relationships between barrier function and clinical parameters. Colonic specimens were obtained from 23 IBD patients before, and at 24 and 52 weeks after VDZ treatment, and from 26 healthy volunteers (HV). Transepithelial electrical resistance (TEER, permeability to ions) and paracellular permeability were measured in Ussing chambers. IBD patients showed increased epithelial permeability to ions (TEER, 13.80 ± 1.04 Ω × cm2 vs. HV 20.70 ± 1.52 Ω × cm2, p < 0.001) without changes in paracellular permeability of a 4 kDa probe. VDZ increased TEER (18.09 ± 1.44 Ω × cm2, p < 0.001) after 52 weeks. A clinical response was observed in 58% and 25% of patients at week 24, and in 62% and 50% at week 52, in ulcerative colitis and Crohn’s disease, respectively. Clinical and endoscopic scores were strongly associated with TEER. TEER < 14.65 Ω × cm2 predicted response to VDZ (OR 11; CI 2–59). VDZ reduces the increased permeability to ions observed in the colonic epithelium of IBD patients before treatment, in parallel to a clinical, histological (inflammatory infiltrate), and endoscopic improvement. A low TEER predicts clinical response to VDZ therapy.